150 related articles for article (PubMed ID: 12147712)
1. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Mad'arová J; Lukesová M; Hlobilková A; Strnad M; Vojtesek B; Lenobel R; Hajdúch M; Murray PG; Perera S; Kolár Z
Mol Pathol; 2002 Aug; 55(4):227-34. PubMed ID: 12147712
[TBL] [Abstract][Full Text] [Related]
2. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
5. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells.
Lu S; Tsai SY; Tsai MJ
Endocrinology; 1999 Nov; 140(11):5054-9. PubMed ID: 10537131
[TBL] [Abstract][Full Text] [Related]
8. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
9. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Lu K; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
[TBL] [Abstract][Full Text] [Related]
10. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
11. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
14. Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3).
Menjo M; Kaneko Y; Ogata E; Ikeda K; Nakanishi M
Oncogene; 1998 Nov; 17(20):2619-27. PubMed ID: 9840925
[TBL] [Abstract][Full Text] [Related]
15. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
Benitez DA; Pozo-Guisado E; Alvarez-Barrientos A; Fernandez-Salguero PM; Castellón EA
J Androl; 2007; 28(2):282-93. PubMed ID: 17050787
[TBL] [Abstract][Full Text] [Related]
17. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
18. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
19. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
20. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
